Impact of nadir PSA level and time to nadir during initial androgen deprivation therapy on prognosis in patients with metastatic castration-resistant prostate cancer
Itsuto Hamano(Hirosaki University), Chikara Οhyama(Hirosaki University), Shingo Hatakeyama(Hirosaki University), Tomonori Habuchi(Akita University), Sadafumi Kawamura(Miyagi Prefectural Hospital Organization), Norihiko Tsuchiya(Yamagata University), Jiro Shimoda(Iwate Prefectural Central Hospital), Shintaro Narita(Akita University), Shigeto Ishidoya(Sendai City Hospital), Koji Mitsuzuka(Pacific Northwest Diabetes Research Institute), Senji Hoshi, Yoichi Arai(Japan Atomic Energy Agency), Toshihiko Sakurai(Sojo University), Masahiro Takahashi(Tohoku University), Hiromi Sato(Akita University), Masanori Ishida(Iwate Prefectural Central Hospital), Tatsuo Tochigi(Miyagi Prefectural Hospital Organization), Toshiaki Kawaguchi(Aomori Prefectural Central Hospital)
Cited by 40
Related Papers
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
|The Lancet Oncology|2017|1.8k
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
|New England Journal of Medicine|2020|1.5k
Prospective Randomized Phase II Trial of a Single Early Intravesical Instillation of Pirarubicin (THP) in the Prevention of Bladder Recurrence After Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma: The THP Monotherapy Study Group Trial
|Journal of Clinical Oncology|2013|253